The findings from our in vitro and in vivo studies on the effects of SCO on adipocyte development and function and insulin action indicate its potential as a therapeutic capable of promoting metabolically advantageous changes in the context of obesity/T2DM. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.